Consensus on the Cosmetic Use of a Novel Botulinum Neurotoxin Type A Product (NEWLUX®) for Facial Expression Muscles: 2024 Guidelines and Discussions by Korean Experts
Toxins · 2025
DOI: 10.3390/toxins17020061 ↗Kurz gefasst
Leitlinie in der Zeitschrift Toxins, 2025. Verfasst von Nark-Kyoung Rho und 9 weiteren Autor:innen. Beteiligte Einrichtung: Leaders Aesthetic Laser and Cosmetic Surgery Center, Seoul 06014, Republic of Korea. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Facial Muscles, Cosmetic Techniques, Facial Expression. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Botulinum neurotoxin type A (BoNTA) is widely used in aesthetic facial rejuvenation medicine. The exponential growth in using BoNTA for cosmetic purposes in Korea necessitates an update to the existing practice guidelines, building upon the consensus established by Korean experts in 2013.
Aims
This work aims to provide an updated Korean consensus guideline for the safe and effective use of a novel BoNTA product (NEWLUX) for facial expression muscles.
Methods
A panel of ten Korean experts in dermatology, plastic surgery, aesthetic medicine, and clinical anatomy convened in February 2024. They reviewed prior guidelines, including the 2013 Korean consensus, and shared their expertise on dosage, injection techniques, and potential complications associated with the use of the novel BoNTA product for facial expression muscles. The recommendations aimed to guide the best practices of the average aesthetic healthcare professional.
Results
The panel reached a consensus on various aspects of using the BoNTA product, including recommended injection sites, dosages, and techniques for different aesthetic conditions caused by facial expression muscles. The resulting guideline emphasizes safety and efficacy, with recommendations based on the collective experience of the expert panel.
Conclusion
This updated consensus guideline provides practical recommendations from Korean experts on the use of the novel BoNTA product for facial expression muscles. The guidelines will ensure safe and effective treatments while reflecting the latest advancements in the field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Leaders Aesthetic Laser and Cosmetic Surgery Center, Seoul 06014, Republic of Korea.
- Rose Dermatology Clinic, Seongnam 13555, Republic of Korea.
- Grace Plastic Surgery, Seoul 06524, Republic of Korea.
- You&Chung Skin Clinic, Seoul 06062, Republic of Korea.
- Pygmalion Clinic, Seoul 06070, Republic of Korea.
- Maylin Clinic, Goyang 10391, Republic of Korea.
ORCID-Profile: Nark-Kyoung Rho, Moon Seop Choi, Hoon-Young Kim, Hyoung Moon Kim, Yong Woo Lee, Wu-Chul Song
Zitieren
APA
Rho, N. K., Bae, G. Y., Choi, M. S., Chung, W. K., Kim, H. Y., Kim, H. M., Lee, H. K., Lee, Y. W., Oh, W., & Song, W. C. (2025). Consensus on the Cosmetic Use of a Novel Botulinum Neurotoxin Type A Product (NEWLUX®) for Facial Expression Muscles: 2024 Guidelines and Discussions by Korean Experts. Toxins. https://doi.org/10.3390/toxins17020061
Vancouver
Rho NK, Bae GY, Choi MS, Chung WK, Kim HY, Kim HM, et al. Consensus on the Cosmetic Use of a Novel Botulinum Neurotoxin Type A Product (NEWLUX®) for Facial Expression Muscles: 2024 Guidelines and Discussions by Korean Experts. Toxins. 2025. doi:10.3390/toxins17020061
BibTeX
@article{Rho2025,
author = {Rho, Nark-Kyoung and Bae, Gee Young and Choi, Moon Seop and Chung, Woon-Kyong and Kim, Hoon-Young and Kim, Hyoung Moon and Lee, Hong-Ki and Lee, Yong Woo and Oh, Wook and Song, Wu-Chul},
title = {Consensus on the Cosmetic Use of a Novel Botulinum Neurotoxin Type A Product (NEWLUX®) for Facial Expression Muscles: 2024 Guidelines and Discussions by Korean Experts},
journal = {Toxins},
year = {2025},
doi = {10.3390/toxins17020061}
}
EUVIMED